REVELATION BIOSC -CW27 (REVBW)       0.0318  +0 (+6%)

0.0318  +0 (+6%)

REVELATION BIOSC -CW270.0318

NASDAQ:REVBW (2/3/2023, 7:04:53 PM)+0 (+6%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector N/A
GICS Industry N/A

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 0 Shares N/A
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO N/A N/A

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

REVBW Daily chart

REVBW News

News Image6 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress

SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

News Image6 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

News Image6 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Pricing of $5 Million Public OfferingNews Image6 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

News Image7 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences...

News Image8 months ago - Revelation Biosciences, Inc.Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

-Data anticipated in Q3 2022-...

REVBW Twits

Here you can normally see the latest stock twits on REVBW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example